Cytokinetics (CYTK) Stock Price, News & Analysis

Company Overview

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications. Cytokinetics has also developed omecamtiv mecarbil, an investigational cardiac myosin activator, and reldesemtiv, an investigational fast skeletal muscle troponin activator for neuromuscular disorders. The company continues to evaluate additional compounds and research programs involving cardiac and skeletal muscle mechanisms.

Founded in 1998 and headquartered in South San Francisco, California, Cytokinetics conducts research and clinical development activities through collaborations and studies in the United States and international markets. Robert I. Blum serves as the company’s president and chief executive officer. Cytokinetics’ products remain primarily in development, and the company’s commercial focus is centered on advancing potential therapies through clinical testing and regulatory review.

Key Stats

• Today's Range: $60.89 to $62.44
• 50-Day Range: $61.12 to $79.20
• 52-Week Range: $56.98 to $88.31
• Volume: 985,624 shs
• Average Volume: 2.04 million shs
• Market Capitalization: $7.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $105.44
• Consensus Rating: Moderate Buy

Cytokinetics Stock Analysis - MarketRank™

Cytokinetics scored higher than 54% of companies evaluated by MarketBeat, and ranked 391st out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 19 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Cytokinetics has a consensus price target of $105.44, representing about 72.2% upside from its current price of $61.23.

Amount of Analyst Coverage

Cytokinetics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytokinetics are expected to grow in the coming year, from ($5.97) to ($4.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytokinetics is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytokinetics is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.95% of the float of Cytokinetics has been sold short.

Short Interest Ratio / Days to Cover

Cytokinetics has a short interest ratio ("days to cover") of 8.37.

Change versus previous month

Short interest in Cytokinetics has recently increased by 10.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytokinetics does not currently pay a dividend.

Dividend Growth

Cytokinetics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.36

News Sentiment

Cytokinetics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Cytokinetics this week, compared to 10 articles on an average week.

Search Interest

Only 1 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,543,855.00 in company stock.

Percentage Held by Insiders

2.60% of the stock of Cytokinetics is held by insiders.

Percentage Held by Institutions

Cytokinetics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/24/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CYTK
• CIK: 1061983
• Web: www.cytokinetics.com
• Phone: (650) 624-3000
• Fax: 650-624-3010
• Employees: 673
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Cytokinetics: $105.44
• High Price Target: $140.00
• Low Price Target: $84.00
• Potential Upside/Downside: +72.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$784.96 million
• Net Margins: -1,321.12%
• Pretax Margin: -1,321.12%
• Return on Equity: N/A
• Return on Assets: -51.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.66
• Quick Ratio: 6.66

Sales & Book Value

• Annual Sales: $88.04 million
• Price / Sales: 86.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.39) per share
• Price / Book: -11.36

Miscellaneous

• Outstanding Shares: 124,430,000
• Free Float: 121,198,000
• Market Cap: $7.62 billion
• Optionable: Optionable
• Beta: 0.41